PHIL420

Patient Advocate since 1977


Leave a comment

What Happens When Germany Has One Million Cannabis Patients? (804,687,322 pounds?) – by Bill Griffin / Marijuanatimes.org

https://www.marijuanatimes.org/what-happens-when-germany-has-one-million-cannabis-patients/

Germany – the EU’s most populous state with 82 million people – is about to offer cannabis on medical insurance. When that happens, demand will soar.

Germany’s lower house of parliament passed a bill legalizing the production, sale and use of medical marijuana on January 19th, 2017.

The bill is restricted to the sale and use of cannabis to patients, and there is no provision for home growing. This means that all cannabis (sold legally) in Germany will come via a doctor’s prescription and from a pharmacy – just like any other prescription drug.

This ensures that the cannabis distributed is of a consistent quality and, most importantly, a consistent strength. It doesn’t ensure that it is especially interesting for cannabis connoisseurs or recreational users in terms of look, taste, smell or effects.

But thanks to the German bill, cannabis will be available through health insurance plans, which is a good thing as currently what is available in the pharmacy is a lot more expensive than what you can buy on the streets.

“Those who are severely ill need to get the best possible treatment and that includes health insurance funds paying for cannabis as a medicine for those who are chronically ill if they can’t be effectively treated any other way,” said Health Minister Hermann Groehe to Reuters.

Beginning last year, Germany has been distributing cannabis flowers through pharmacies on a case per case basis. This created a sizeable market of a few thousand patients that – due to the fact that Germany does not currently allow the cultivation of cannabis – is met through imports from (legal) cannabis producing countries, such as the Netherlands and Canada.

This is going to change. Companies are already rapidly putting together blueprints and applications to legally cultivate cannabis in Germany. Some of these companies are already importing and building up their distribution contacts and networks. As soon as they have the green light to cultivate, they will be building local facilities to meet the increasing demand.

Just how big this demand will be is currently based on estimates. Germany is a cannabis-friendly country, with 23.1% of the adult population having consumed cannabis. That’s nearly 19 million people, which given cannabis’ illegality at the time of the survey will include both medical and recreational users. To put things in perspective, Germany’s population is more than double that of California, with 82 million versus 39 million inhabitants.

Let’s say a conservative estimate of people enrolled on Germany’s medical cannabis programme will be a cool one million.

If an average patient consumes 1 gram per day – which is low or high, depending on your ailment – that would mean each patient would require 365 grams per year. Multiply that by a million and we are talking 365 metric tons – or 804,687,322 pounds. That’s a lot of pot and it’s going to take a lot of cultivation space to produce.

Who’s going to grow it?

As there is no entrance into the market for home growers or caregivers like in many U.S. states, this is going to have to be produced by companies running facilities with good agricultural practice (GAP), good distribution practice (GDP) and good manufacturing processes (GMP). You don’t get to distribute any drug in a pharmacy without such high quality control – especially in Germany.

As you can imagine, this is creating a feeding frenzy for big actors in the cannabis industry. In April, they will be convening in Berlin for the first European-based International Cannabis Business Conference. Local players with cultivation licenses will be seeking capital to meet the exacting requirements that only Germany can define. International money men will be homing in on those that can give them a great return on investment in this soon-to-be exceedingly lucrative market.

The result will be that patients in Germany will have safe access to cannabis-related medicines.

Every time a patient visits the pharmacy, they know that what they are going to get will be more or less the same as what they had the previous time. Their cannabis will be grown without human intervention in automated cultivation rooms. Biological engineers will be monitoring the grow installation and laboratories will test the end product to ensure that the cannabinoid profiles will remain consistent from batch to batch.

Once complete, the buds will be irradiated of soil microorganisms and they will be packaged and stored in perfect conditions until it is handed to the patient in a white paper bag and a smile from their local pharmacist.

All cannabis culture has been methodically stripped out of the cannabis that will be distributed.

As a hobby home grower and recreational user – self-medicating in the absence of legislation that will allow me to get a prescription – I find this a rather sad ending to the calls for legalisation from millions of Europeans over the last 50 years. I have to admit, for many patients getting true medicinal grade cannabis free from pests, diseases or any adulterants is a good thing; growing cannabis to this level of consistency at home is virtually impossible. I’m not discounting it for recreational use, but in the way we class “medicine” in modern society it is not something that we produce in our homes – that’s called a “remedy”. Collectively and with empirical data to back it up we have agreed that medicine should be sterile. Cannabis from your greenhouse is far from sterile.

This arrangement will line the pockets of big investors and local entrepreneurs, but will also provide safe medicine to those who need it most. People who would never dream of growing their own or sourcing through a network of growers will be able to benefit from a medicine that has no adverse side effects.

The genie will be well and truly out of the bottle. More people in society will come to accept cannabis and see that the negative propaganda of the past was based on lies.

Increased cultivation, distribution and monitoring of patients will provide data that will have positive results. Science will finally be able to study cannabis, cannabinoids, terpenes and all the other components that make up the cannabis plant. This will lead to more breakthroughs and medical applications.

Germany is the largest population in Europe, and once they show that this can work, other countries will inevitably follow their lead.

However, for many activists this is not the end game; cannabis through pharmacies is just phase one. Ultimately, Germany will legalize cannabis for recreational use. That’s how it works, just look at the pattern in the U.S. and Canada. First, you legalize for medical use, then you decriminalize for recreational use, then you get full on legal cannabis to anyone who is old enough to buy it.

When that day comes there won’t just be one million medical patients; the full 23.1% of the German population that tried it will be able to consume without the guilt or anxiety that prohibition creates. This demand could only be met from decentralised local producers. This is where the connoisseurs will benefit. I dream of the day when, instead of dropping in my local wine shop, I stop by my local cannabis dispensary to see what delights they have on offer. It’s some way off at the moment, but my money’s on this becoming a reality in the not-too-distant future.


Leave a comment

Foreign Corrupts Practices Act (FCPA) – by Simone Cimiluca Radzins

https://www.cannabisbusinessexecutive.com/2017/03/building-global-cannabis-brand-heres-one-law-need-know/

Many US brands are already working in the international cannabis market, through licensing out their product/service to other countries. But beyond the glory of carrying an international brand, there are certain risks of taking your cannabis brand global.Barriers to entry are tough in a foreign market, and making personal connections with foreign officials is key to integrating a brand into a new market. However, what did it take to get the brand into that country? Did it take a few meals or gifts to someone from the government? If so, there could be a violation of the Foreign Corrupts Practices Act.

What is the Foreign Corrupts Practices Act (FCPA)?

Congress enacted the FCPA in 1977 after revelations of widespread global corruption and discovering that more than 400 U.S. companies had paid hundreds of millions of dollars in bribes to foreign government officials to secure business overseas. The Department of Justice (DOJ) and SEC started heavily pursuing companies (Walmart, Seimans, etc) in 2012.

The FCPA is known primarily for two of its main provisions, one that concerns bribery of foreign officials and the other that addresses accounting transparency requirements under the Securities Exchange Act of 1934.

As mentioned above, there are two main provisions in the FCPA, which include:

  • Bribery of Foreign Officials: It is illegal for companies and individuals to influence a foreign official (or third parties/intermediaries to foreign officials) with any personal payments or rewards. This includes not only cash payments; it also may include travel and entertainment expenses or expensive gifts.
  • Accounting Transparency: The FCPA requires companies whose securities are listed in the United States to meet its accounting provisions.The accounting provisions also prohibit individuals and businesses from knowingly falsifying books and records or knowingly failing to implement internal controls.

How do you define what type of payments would be in violation of the FCPA? According to the FCPA, “payments intended to induce or influence a foreign official to use his or her position in order to assist … in obtaining or retaining business for or with, or directing business to, any person.”  Obtaining or retaining business can be defined as winning a contract, influencing the procurement process, avoiding contract termination, and more.

What you can do to ensure compliance with the FCPA

Companies engaging in business in emerging markets face a uniquely increased level of corruption and regulatory risk, but like everything – there are solutions. Here are three things that your company can do to mitigate FCPA risk.

1. Training: Implement a basic training program at your company. This training program should include all forms of compliance (code of conduct, sexual harassment, etc) and a separate FCPA training program.  Ensure that the accounting department, sales team, executive management, and the board of directors are trained.

2. Contracts: Include a FCPA clause in all contracts for customers and vendors.

3.  Monitoring: Continually monitor all controls that are in place to mitigate FCPA. This includes review of contracts and training requirements. An internal audit of transactions is also recommended depending on the size of operations.

FCPA does not mean zero contact with foreign officials. Under the FCPA, individuals still are able to engage and have an open dialogue with government officials. Gifts of “reasonable” value are allowed, if allowed by local law. However, there needs to be a clear internal structure to ensure full compliance with the law.

If you’re in cannabis, you’re in compliance. Global compliance is another game, make sure you’re prepared!

 


Leave a comment

ICBC Berlin Speakers – wow!

http://internationalcbc.com/bios/

U.S. Congressman Dana Rohrabacher

Currently serving his 13th term in Congress, Dana Rohrabacher represents California’s scenic 48th District. He also serves as Chairman of the Europe and Eurasia Subcommittee of the House Committee on Foreign Affairs and is Vice Chairman on the House Committee on Science, Space and Technology. Rohrabacher is a strong voice for lower government spending and taxes. His record of fiscal restraint and pro-growth policies has won him acclaim from the National Taxpayers Union, Citizens Against Government Waste, the U.S. Chamber of Commerce and the National Federation of Independent Business.

Tommy Chong

Perhaps the most iconic name in all of cannabis, Tommy Chong is best known for his role in the classic Cheech & Chong movies that set the stage for the future of cannabis comedy. A tireless cannabis activist, Tommy Chong has continued his career in the cannabis industry to this day, and is now leading a well-branded line of cannabis products called Chong’s Choice.

Dr. Franjo Grotenhermen, MD

Born in 1957, academic studies of medicine at the University of Cologne. He is running a medical practice, mainly devoted to the medical use of cannabis and cannabinoids. Dr. Grotenhermen is founder and chairman of the German Association for Cannabis as Medicine (ACM), founder and executive director of the International Association for Cannabinoid Medicines (IACM) (www.cannabis-med.org) and chairman of the Medical Cannabis Declaration (MCD). He is editor of the IACM-Bulletin, which is published bi-weekly in several languages and editor of the internet journal CANNABINOIDS, published on the website of the IACM. He is a principal of the nova-Institute based near Cologne and author of many articles, books and book chapters on the therapeutic potential, pharmacology and toxicology of the cannabinoids.

Dr. Donald Land, PhD

As Chief Scientific Consultant, Dr. Land guides the Science and Product Development groups at Steep Hill. His role includes optimizing scientific processes in the business, developing best practices, and evaluating new business opportunities from a scientific perspective. Dr. Land co-founded Halent Laboratory in 2010, which was then a major competitor to Steep Hill,later merging Halent into Steep Hill in 2013, to unite the two leading cannabis science firms. Dr. Land is a nationally recognized scientific expert on the chemistry of the cannabis plant and is in great demand as an educational speaker on its effects.

Dr. Land is also a currently a tenured professor at UC Davis where his research spans the fields of Forensic Science, Biotechnology and Sensor Development. Dr. Land is a member of the UC Davis Forensic Science Graduate Group and the Designated Emphasis in Biotechnology, in addition to his continuing position in Chemistry. At UC Davis, he developed a program in interfacial analytical chemistry and a wide-ranging program in forensic chemistry.

Dr. Land received a PhD from the University of California, Irvine where he developed novel techniques using laser-induced thermal desorption with Fourier transform mass spectrometry, along with electron and ion spectroscopies. His work at UC Irvine earned him an IBM Corporation Graduate Research Fellowship, as well as a prestigious Alexander von Humboldt Fellowship to conduct postdoctoral research in surface vibrational spectroscopy at the KFA Researchzentrum in Jülich, Germany. Dr. Land was subsequently hired as an Assistant Professor in the Department of Chemistry at the University of California, Davis in 1991, at just 28 years of age.

Dr. Pierre Debs, PhD

is a scientist with 25+ years academic research experience with genetic engineering, stem cell biology, somatic cell reprogramming and the endocannabinoid system. After a family member with cancer began successfully self-medicating with cannabis extracts, Pierre started searching the scientific literature for clues as to why full spectrum cannabis extracts were helping, and found very little.  At the same time, he started studying the endocannabinoid system in cancer cells culture, then in various stem cells. In 2015 he left the lab and cofounded MedCann GmbH with the goal to produce cannabis medicines giving German patients more choices, to drive medical cannabis awareness and support clinical research. By the end of July 2016, MedCann had successfully imported medical cannabis from Canada and started distribution to German Pharmacies. Going from biological research direct to CEO of a cannabis start-up is an interesting adventure, more so in Germany. By the end of 2016, MedCann was acquired by Canopy Growth Corporation underscoring the importance of Germany to the growing European Cannabis Industry.

Dr. Ingo Michels, MD

Is currently working for the Institut of Addiction Research and as International Coordinator of the EU Central Asia Drug Action Programme (CADAP) at the University of Applied Sciences in Frankfurt on Main, Germany. Had been working for a long period as Head of Unit of Federal Drug Commissioner of the Ministry of Health, Germany.

A sociologist and advisor for treatment of drug dependency, Dr. Michels has served as Head of the Drugs and Prison projects department of the German AIDS-Hilfe in Berlin, as Drug Commissioner of the Federal State of Bremen, Germany, and as Head of the Office of the Federal Drug Commissioner, Federal Ministry of Health in Berlin, Germany.

In 2007 he worked as a Consultant for the German International Development Organization GTZ (Gesellschaft für Technische Zusammenarbeit – Association for Technical Cooperation) on “HIV prevention among injecting drug users through harm reduction capacity building and advocacy” in Vietnam, Ukraine and Pakistan. Dr. Michels has published widely in international journals on substance use.

Dr. Reggie Gaudino, PhD

As Vice President for Science and Intellectual Property at Steep Hill, Dr. Gaudino is building the company’s Ynsight™ genetic analysis division as a companion to Steep Hill’s successful chemical profiling and chemical testing business. As Director of Genetics, Dr. Gaudino has been recognized as a leader in the field of cannabis genetics and was recently featured in Wired Magazine.

He is building a team to produce the highest quality and respected scientific results suitable for peer review in the field of cannabis research. Steep Hill will bring these scientific advancements to market for growers, breeders, and ultimately consumers. Dr. Gaudino also oversees the dayto- day scientific operations of Steep Hill’s laboratories in California, New Mexico and Washington, to insure they continue to define, lead and exceed industry standards. In addition, Dr. Gaudino identifies new IP opportunities and protects existing Steep Hill IP, through aggressive patent and trademark filing and prosecution.

Prior to his role at Steep Hill, Dr. Gaudino served as a published genetic researcher with 18 years of intellectual property experience in writing, prosecuting and managing patents and patent portfolios in fields as diverse as software and telecom to biotechnology and molecular genetics. Dr. Gaudino came to Steep Hill from Sequenom, Inc. (NASDAQ: SQNM) where he served as a Patent Agent. Previously, Dr. Gaudino managed IP based acquisitions for the Vortice Research Group, and he also has worked at several law firms such as Grant Anderson LLP, Biotechnology Law Group, Gray Cary Ware & Freidenrich and Lyon & Lyon, in addition to serving as an advisor and consultant to portfolio investment companies.

Dr. Gaudino received his B.S. in Molecular Biology and Ph.D. in Molecular Genetics from the State University of New York at Buffalo, and he conducted four years of post-doctoral research at the Washington University in St. Louis, studying transcriptional regulation of rRNA.

Linn Baumgardt

As Leafly’s Director of Marketing, Linn Baumgardt continuously strives to elevate the cannabis industry by breaking through barriers and partnering with mainstream companies such as Pandora and Twitter. Linn’s creativity, strategic mindset and drive to push boundaries have been invaluable in establishing Leafly as the fastest-growing privately held company in the Pacific Northwest. By analyzing market trends and legislation around the world she created a custom algorithm that has become the standard for how Leafly approaches new regions and global markets.

In addition, Linn launched Leafly’s largest media campaign, Leafly Vote, in support of cannabis legalization in nine states. Prior to Leafly, Linn worked with companies such as Microsoft, Discovery Channel, and consulted for clients such as Amazon, Sprint, and Red Box.

Jürgen Bickel

Jürgen Bickel is one of two managing partners at STORZ & BICKEL GmbH & Co. KG, the manufacturer of the first and –to date- only medical cannabinoid vaporizers on the market.

He holds a degree in civil engineering and acted as an international development worker in Peru for 5 years in the late 90ies, where he was dedicated to the water and sanitation sector in different cities like Chiclayo, Ayacucho and Tumbes.

In 2002, Jürgen Bickel joined Markus Storz, inventor of the VOLCANO Vaporization System as a partner and STORZ & BICKEL GmbH & Co. KG was founded. Together, they established a fast growing and international business with highly demanded products. In 2016, STORZ & BICKEL built its “S&B Vapor Factory” in Tuttlingen, Germany, a town with a reputation for being the nexus of medical technology with nearly 500 medical device manufacturers located there. With the VOLCANO MEDIC and the MIGHTY MEDIC, STORZ & BICKEL provided the only validated application method for the administration of cannabinoids, which was crucial for the overall acceptance of cannabis as medicine.

Dr. Jokūbas Žiburkus, PhD

Dr. Jokūbas Žiburkus, PhD is a neuroscientist with over 20 peer-reviewed publications and book chapters. He is a tenured Associate Professor at the University of Houston where his research is focusing on epilepsy, traumatic brain injury, and Alzheimer’s disease. The laboratory’s current focus is on cannabinoid actions in the brain and novel treatments for neurological disorders. Žiburkus is a recipient of both the Global Lithuanian Leader Award for intellectual capital dissemination and the University of Houston’s Teaching Excellence Award. He is a recognized public speaker with a widely watched Tedx Talk entitled, “There is something you should know about epilepsy and cannabis.” Žiburkus currently serves on several prestigious scientific, business, and editorial boards, including Dravet Syndrome Foundation’s Scientific and Medical Advisory Board. He is also a co-founder of CannTelligence,an educational and biotechnological innovation hub for cannabis industry-related projects.

Marc Lustig

Mr. Lustig holds MSc and MBA degrees from McGill University. He began his professional career in the pharmaceutical industry at Merck & Co. In 2000, he started his capital markets career in institutional equity research in the Life Sciences sector at Orion Securities. For the next 14 years, Mr. Lustig worked as a Director at GMP Securities L.P. and as Head of Capital Markets at Dundee Capital Markets before becoming a Principal at KES 7 Capital. Mr. Lustig founded Cannabis Royalties & Holdings Corp. in early 2015.

Dr. Pavel Jeřábek

Dr. Jeřábek works in the Czech State Institute For Drug Control (SÚKL – State Agency for Medical Cannabis) as a medical cannabis specialist and cannabis inspector.

Dr. Pavel Kubů, MD

Dr. Pavel Kubů is an expert in the fields of medical informatics and addictology.

In 2001, he graduated in general medicine with a focus on disease prevention and public health from the Third Faculty of Medicine, Charles University.

Since 2005 he has been working for the Intel Corporation as a Business Development Manager, leading projects of the Intel World Ahead Programme for Healthcare in Central and Eastern Europe and Education in the Czech Republic and Slovakia.

In 2006 he was appointed as chair of the Ethics Commission at the National Monitoring Centre for Drugs and Addiction.

Pavel has served since 2007 as a board member of the Czech National Forum for eHealth, from 2012 to 2015 as a member of the steering committee of the Czech Healthcare Forum and since 2013 as a board member of the medical cannabis patients’ organisation KOPAC. In these non-profit NGOs he is primarily devoted to the education of healthcare professionals, patients and caregivers and support for the research and development of new treatment and preventive methods.

In 2014 he became a cofounding member of Konomed, a company that focuses on research and development in the field of medical cannabis that was transformed to ICCI – International Cannabis and Cannabinoids Institute in 2016. ICCI founders share combined experience that includes clinical and basic research, direct patient advocacy, legislative efforts and studies, government relations, advisory and administration, medical informatics, the creation of product safety protocols such as quality control / quality assurance standards and laboratory analysis for the cultivation, manufacturing and distribution of cannabis products and global entrepreneurship. Their unique position leverages unparalleled resources and experience to create a global cannabis resource.

Steve DeAngelo

Steve DeAngelo, Executive Director of Harborside Health Center in Oakland, California, is a cannabis industry leader, movement strategist and lifelong activist. Steve writes and speaks widely on the subject of cannabis, and his creation of the world’s model medical cannabis dispensary has been extensively covered in national and international news media.

His past accomplishments include organizing I- 59, Washington D.C.’s medical cannabis initiative; Hemp Tour, which brought hemp to the heartland; and Ecolution, Inc., which produced hemp garments and accessories 1990-2000. A Summa Cum Laude graduate of the University of Maryland, Steve is a founding, charter member of ASA (Americans for Safe Access); on the board of the Emerald Growers Association and the star of the Discovery Channel mini series, “Weed Wars” which is currently rolling out internationally.

Matei Olaru

Matei Olaru is the CEO of Lift, Canada’s most recognized cannabis media and technology company. A corporate lawyer and consultant by trade, Matei practiced law for the cannabis industry before joining Lift in 2016. Prior to that, Matei helped advise governments on business and investment policy as a consultant with the World Bank (IFC). Matei holds a law degree and a business degree, and has studied internationally in Italy and Singapore.

Georg Wurth

Georg Wurth is a former local politician of Germany’s Green Party. He has lead the German Hemp Association (DHV) since its foundation in 2002. The organisation is one of Europe’s biggest organizations calling for the regulation of recreational and medical cannabis. With 150,000 Facebook fans and more than 3 million Youtube views, the DHV is powerful on social media. After winning a popular vote, Georg became the first cannabis lobbyist to speak to German Chancellor Merkel about reform. In 2014 Georg’s reform campaign idea won one million Euros on a televised show, after which he launched Europe’s first cinema spot campaign against prohibition.

Ophelia Chong

Ophelia Chong is the creative genius behind Stock Pot Images and Asian Americans for Cannabis Education (AACE). She is driven to help shape the new conversation of Cannabis and is guided by one mission: to advocate for the legalization of cannabis and offer truthful reflections of the faces and communities that embrace cannabis.

After graduating from the Art Center College of Design in 1989, she traveled the world for a few years and found her calling in photography. She began her career as the photographer for David Carson at Raygun Magazine, Sony Music, Mercury, Epitaph, and Interview Magazine. She went on to become the creative director at Strand Releasing, distributing over 50 films to the Sundance, Toronto, New York, Venice, Berlin and Outfest film festivals.  She moved into the stock and assignment photography business next. Since 1999, she has specialized in marketing and designing for photographers, photography monographs and photography agencies.

Ophelia teaches Marketing and Self-Promotion to photography students at the Art Center College of Design since 2010 and is an art director in the MFA writing program at CalArts since 2008.

Alan Dronkers

Ben Dronkers’ eldest son, Alan is a highly skilled and knowledgeable breeder and an integral part of Sensi Seeds breeding programs which took place at the now-legendary Cannabis Castle. Alan possesses an enormous wealth of information about medicinal and industrial cannabis genetics. He also takes a keen interest in the history and use of cannabis around the world as well as in the laws pertaining to the plant.

Alex Rogers

Visionary entrepreneur and political activist, Alex Rogers, is the founder and CEO of three thriving ancillary cannabis businesses. Cutting his teeth as an activist in the early nineties under the tutelage of Jack Herer, Alex has a deep proprietary knowledge of the industry. He has played a key role in professionalizing and mainstreaming the cannabis industry, building one of Oregon’s most popular medical marijuana clinics in a matter of a few years, and the first ever to advertise medical marijuana on network TV in America. He also founded and runs the Oregon Marijuana Business Conference (OMBC), the state’s biggest and longest running cannabis business conference. Living in five different countries throughout his life, and able to communicate in all respective languages, Alex considers himself an international citizen, thusly spawning his latest creation, the International Cannabis Business Conference (ICBC). The ICBC is the first and only cannabis business conference in the world to have multiple dates set in multiple different countries. A Magna Cum Laude graduate in Political Science, he has used his knowledge of law and politics to push cannabis policy forward all over the world.

Debby Goldsberry

Debby Goldsberry has 25 years as a leader in the medical and adult use marijuana industry. She co-founded the Berkeley Patients Group (BPG) medical cannabis collective in 1999. Directing its growth over 11 years, with 70 employees and up to 1,000 customer visits per day. At BPG, Ms. Goldsberry developed and implemented standard operating procedures for procurement, product safety, patient relations, and business management and operations, which have been replicated by dispensaries around the nation. As a community leader, she co-founded and directed Americans for Safe Access (ASA), Medical Cannabis Safety Council (MCSC), and Cannabis Action Network (CAN). She is a board member at California NORML, is a former board member of the Marijuana Policy Project, and teaches procurement and patient relations at Oaksterdam University. She has proven experience in business and human resources management, public and government relations, and product development and marketing. Ms. Goldsberry is currently the Ambassador at Magnolia Wellness in Oakland, CA and at Bloom Well in Bend, OR, two model medical cannabis dispensaries.

Ognjen Brborovic

Born 1972 in Zagreb, Croatia. Graduated on Medical School, University of Zagreb in 1998. In 2005 finished postgraduate studies in Public Health and successfully finished residency in Public Health. In 2010 acquired PHD with the thesis Association of formal education and pressure for changing health habits to self-perceived mental and physical health. In 2014 he became Assistant Professor at the Department of Healthcare Organization.

He is author in 20+ scientific papers published in peer reviewed journals.

Since 2003 he is one of the directors of symposium Media and Health that each year gathers most prominent Croatian journalists, politicians and professionals in health & healthcare area. In 2012 he became vice-president of Croatian Public Health Society, one of the societies of Croatian Medical Association.

As a vice-president of Croatian Public Health Society he advocated medical usage of cannabis on numerous occasions, in private encounters, public lectures and media. At the end of 2014 Croatian Minister of Health appointed him as a President of Minister Committee on Medical Cannabis that has successfully finished first phase of work with legal changes necessary to deliver cannabis medicine to patients. Committee’s further tasks are to track medical usage and abuse of cannabis, suggests improvements, indications and guidelines for medical professionals.

Marguerite Arnold

Marguerite Arnold is an American expat with German entrepreneurial roots. She has worked and lived in three countries (the U.S., UK and Germany).

She has over 25 years experience in the digitalization of industries (media, transportation/supply chain, structured finance and FinTech specifically) with stints at and for companies including Reuters, Morgan Stanley and Google. She was nominated for an Ernst & Young Entrepreneur of the Year Award in 1999. She has just finished her EMBA at the Frankfurt School of Finance and Management.

She is currently in talks with strategic co-founders and company partnerships as well as looking for seed financing for a “weedtech”/insuretech startup in Germany. She also currently covers the industry internationally for various publications in Europe and the U.S.

Sebastián Marincolo

Sebastián Marincolo is a former student of the philosophers William G. Lycan, Simon Blackburn, and Manfred Frank. His research focuses on the philosophy of mind, neurocognition, and on altered states of mind. Marincolo has published various articles on the marijuana high, co-edited bewusstseinserweiterungen (“mind expansions”), an issue of the German internetzine “parapluie”, and published three books on the marijuana high: the study “High. Insights on Marijuana” (Dogearpublishing, Indiana, USA, 2010), the essay collection, “High. Das positive Potential von Marijuana” (in German, Klett Cotta/Tropen, Stuttgart, Germany, 2013), which contains his macro art series “The Art of Cannabis”, and the essay collection “What Hashish Did To Walter Benjamin” (Khargala Press 2015).

Marincolo also worked with marijuana expert Harvard Associate Prof. Emeritus Lester Grinspoon on a book project. For more than five years he was a creative director and consultant for one of the biggest foundations in Germany and has more than 25 years of experience as a freelance photographer. His art photography from New York City, Rio de Janeiro, Bali and other places has been shown in various exhibitions and art galleries in Germany and the U.S. He is currently living in Stuttgart, Germany, and works as a freelance writer, creative consultant and photographer.

Òscar Parés

Òscar Parés Franquero has degrees in philosophy and anthropology and an MA in drug dependencies from the Barcelona University. He is currently the deputy director of the International Center for Ethnobotanical Education Research & Service Foundation (ICEERS). He is the main author of the Drug Policy Report: Catalonia, Innovation Born of Necessity (OSF, 2015) and co-authored the paper “How to regulate Cannabis Social Clubs: analyzing the experiences in Spain, Belgium and Uruguay” (2017 International Journal of Drug Policy). During 7 years he had collaborated with the Government of Catalonia in coordinating risk reduction programs in the nightlife context and, in the context of the regulation of the activity of Cannabis Social Clubs.

Ed Rosenthal

Ed Rosenthal is the world’s leading expert on the cultivation of marijuana. In his more than forty years as the “guru of ganja,” he has written or edited more than a dozen books about marijuana cultivation and social policy that cumulatively have sold over two million copies. His “Ask Ed”® marijuana advice column ran in High Times for several decades and still appears internationally. One of his books on marijuana cultivation is the only book of its type to be reviewed by The New York Times.

Currently Rosenthal consults for commercial growers throughout the world, both independently and as a team member of Quantum 9, a cannabis consulting service. He is also on the faculty of Oaksterdam University, the leading trade school for the cannabis industry. His classes teach pupils how different techniques can be used to improve the yield and efficiency of their gardens.

Beyond the garden, Rosenthal views marijuana law as a crucial social issue and has been active in promoting and developing policies of civil regulation. In 2003 he was tried in federal court for cultivation in a trial where the jury was not allowed to hear that he was deputized by the City of Oakland to provide marijuana for patients. His trial shifted public opinion in favor of state medical marijuana laws. He currently serves as the Executive Director of Green Aid: The Medical Marijuana Legal Defense and Education Fund.  Rosenthal has also served as an expert witness for federal, state, and civil marijuana cases for over thirty years.

Books by Ed Rosenthal include: Protect Your Garden, Marijuana Grower’s Handbook (2010), Marijuana Pest & Disease Control, Medical Marijuana 101, Why Marijuana Should be Legal, and The Big Book of Buds series.

Steve Bloom

Steve Bloom is editor-in-chief of Freedom Leaf magazine. He also publishes and edits CelebStoner.com, one of the leading sources for marijuana and celebrity news on the web since 2007.

Steve was named editor of Freedom Leaf in November 2014.

He’s co-author of Pot Culture: The A-Z Guide to Stoner Language and Life (Abrams Image, 2008) and Reefer Movie Madness: The Ultimate Stoner Film Guide (Abrams Image, 2010).

A former editor of High Times, Steve produced the Stony and Doobie awards shows, and the Hempilation benefit albums for NORML during his more than 15 years with the magazine, from 1989 to 2006.

He was the recipient of NORML’s Media & Culture Award in 2004.

Steve’s also appeared as a moderator, panelist and speaker at many marijuana-reform events, including the NORML conference, the Drug Policy Alliance conference, the International Cannabis Business Conference, Seattle Hempfest, Boston Freedom Rally, Cannabis Peace March, and Cypress Hill’s SmokeOut and Spring Gathering events.

He and Willie Nelson founded the Teapot Party in 2010.

He’s also the author of Video Invaders (Arco, 1982) and Watch Out for the Little Guys (St. Martins Press, 1989).

He lives in Bronx, NY.

Michael Knodt

Michael Knodt was born in Hessen, Germany, and has been living in Berlin since the Berlin Wall fell. He initially studied history and journalism before receiving certification as a carpenter. He has worked as a freelancer for German-language hemp magazines since 2004 and from 2005 to 2013, he was the editor in chief of Germany’s biggest cannabis periodical. Currently, this father of two writes for Vice magazine, marijuana.com, Sensi Seeds, numerous German and English-language publications. He is also the face and presenter of DerMicha, his new YT-Channel on cannabis and its prohibition.

Susan Audino, PhD

Susan Audino obtained her PhD in Chemistry with an analytical chemistry major, physical and biochemistry minor areas.  Susan was the recipient of NSF Chemometric Graduate Fellowship and was a visiting scientist at NIST where she completed her graduate research.  She currently owns and operates a consulting firm to service chemical and biological laboratories, is an A2LA Lead Assessor and Instructor, and serves as a Board Member for the Center for Research on Environmental Medicine in Maryland.  She is also serving as Quality and/or Technical Director for several laboratories and has worked with a variety of laboratories to establish and/or improve their quality management and technical operations.

Susan has been studying the chemistry and applications of cannabinoids and provides scientific and technical guidance to medical marijuana dispensaries, testing laboratories, medical personnel, and regulatory agencies. Dr. Audino’s interest most directly involves marijuana/cannabis consumer safety and protection, and promotes active research towards the development of official/consensus test methods specifically for this industry. Her perspective is that inadequate testing is worse than no testing.  In addition to serving on Expert Review Panels, she has been working closely with AOAC to develop interest and movement toward the development of scientifically sound methodologies for the cannabis sector, and is chairing the first such AOAC Cannabis Working Group.

Guenter Weiglein

Of the legal cannabis users in Germany, three patients have been able to take their cases against the Federal Institute for Drugs and Medical Devices (BfArM) for not allowing them to grow their own plants since the imports are incredibly expensive and not covered by health insurance.

Günther Weiglein is one of the three cannabis patients who the German court allowed the ability to potentially grow his own medicine.

Dean Arbit

Dean has been a trailblazer in Cannabis related media, helping found Smell the Truth on SFGate in 2011, where he currently serves as Publisher.  In 2015, Dean also conceptualized and co-founded New West Summit, which he sold the following year. Prior to entering the Cannabis space in 2011, Dean served as CEO of West Coast Outdoor Media Inc., which he founded 1998, and he help build into one of the largest independent outdoor advertising companies in the Western U.S., with clients such as Apple, NIKE, and Bank of America. New York-based private equity firm Flexis Capital acquired West Coast Outdoor Media in January of 2011. Dean studied Economics and International Finance at San Francisco State University.

Jamie Shaw

Jamie’s experience in the theatre and film industries saw her take up residence in New York, Toronto, Las Vegas and Los Angeles before locating in Vancouver. She was a Director and spokesperson for the BC Compassion Club Society (BCCCS), and served as President of the Canadian Association of Medical Cannabis Dispensaries (CAMCD). Her successful lobbying for these organizations Dispensary led the city of Vancouver to not only develop bylaws for dispensaries, but to create a separate class of license for compassion clubs like the BCCCS, that requires membership in CAMCD.

Jamie co-founded the Women Grow Vancouver Chapter, and is a prolific writer whose work is featured on the websites Canlio, and Lift. She continues to consult, lobby and advocate for dispensaries, and currently serves in the role of Government Relations for MMJ Canada.

Aaron Smith

Aaron Smith is the co-founder and executive director for the National Cannabis Industry Association (NCIA) – the only national trade association representing the social and political interests of legal cannabis businesses in the United States. Founded in 2010 and now representing nearly 1,000 member businesses, NCIA maintains offices in Washington, D.C. and Denver, Colorado.

Prior to launching NCIA, Aaron distinguished himself as a public advocate for common sense marijuana policy reforms — first under the auspices of a California-based medical cannabis advocacy group, Safe Access Now, and later as the California state policy director for the Washington, D.C.-based Marijuana Policy Project. Aaron’s opinion pieces have appeared in major newspapers, including the San Francisco Chronicle, Los Angeles Times, and The New York Times, and he has been a frequent commentator on national television news networks. Originally from the San Francisco Bay Area, Aaron is currently based in Denver, Colorado.

Kirk Tousaw

Kirk Tousaw is a barrister and advocate for law reform. His primary practice areas are Medical Cannabis Regulatory Compliance, Cannabis Criminal Defence and Strategic Litigation.

In addition to the daily practice of law, Kirk advocates for law reform. He sits on the all-volunteer Board of Directors of the British Columbia Civil Liberties Association. He also sits on the Board of NORML Canada, MAPS Canada and the Sensible BC Society. Kirk drafted the Sensible Policing Act, a recent ballot initiative in BC that garnered more than 200,000 signatures.

Kirk has written and spoken extensively on issues related to drug policy, privacy, religious freedom, and criminal justice policy. In addition, Kirk has had the privilege of testifying several times before the Standing Committee on Justice and Human Rights of the House of Commons and also before the Senate Standing Committee on Legal and Constitutional Affairs. In 2015 he litigated the first medical cannabis case to be heard by the Supreme Court of Canada.

Ross Mirkarimi

Ross Mirkarimi was elected the thirty-fifth Sheriff of the City and County of San Francisco, and served until 2016.  Prior to becoming Sheriff, he was elected to the San Francisco Board of Supervisors (City Council) for two terms.  Throughout his 22 years of public service, Ross has been an outspoken advocate for the legalization of cannabis – the only Sheriff in California’s 58 counties.  In 2005, Ross was the first municipal legislator in California to author a comprehensive regulatory framework for legalizing medical cannabis. He received NORML’s “hero of the year” award in 2006. Appointed by the State Senate, Ross also served on the California Costal Commission between 2009-2011.   Since leaving public service, Ross is consulting governments domestic and abroad on criminal justice reforms, and implementation of cannabis regulations.

Ngaio Bealum

Ngaio Bealum is one of the premiere cannabis comics in the United States and you’ll see why he has performed at just about every Hempfest on the West Coast and too many cannabis-related events to even keep track of. He has appeared on Comedy Central, BET, MTV and many other networks and shows across your television dial.  Very recently, he was a featured guest on the hilarious podcast of Doug Benson (Super High Me, Half-Baked), Getting Doug With High. In addition to his cannabis comedy, he is the former editor of West Coast Cannabis Magazine and has been a tireless activist for legalization. While Ngaio’s comedy is hilarious whether you are a full-fledged member of the cannabis community or not, it certainly doesn’t hurt.

Chris Driessen

Chris Driessen is the President of Organa Brands, the Colorado-based parent company of O.penVAPE, Bakked, District Edibles, Magic Buzz and Organa Labs products. Organa Brands is home to the largest consumer cannabis brands in the United States, with ancillary and CBD products in eight European countries. As President, Driessen is responsible for all aspects of day-to-day operations, corporate strategy and overall performance of the organization.

Driessen’s competitive background managing sales efforts for Starwood Hotels and Resorts allowed him to prepare Organa Brands as an international house of brands. Through intensive sales and brand training with Starwood (and other international hotel enterprises), Driessen understands the necessity for brand development and delivering a unique consumer experience. This background paved the way for Driessen to contribute to O.penVAPE becoming the most widely recognized and globally distributed brand in cannabis.

O.penVAPE’s dramatic revenue growth for the past several years is in part due to Driessen’s ability to lead and motivate his sales teams. With his sales leadership experience with Konica Minolta Business Solutions, one of the largest technology companies with offices in 49 countries worldwide, he brings systematic practices and highly developed organization skills to Organa Brands. He is responsible for tripling the size of Organa Brands’ licensee network within the United States and expanding the company’s international presence into both Europe and the Caribbean. The company revenues have grown 10X under his leadership as both a sales leader and executive.

As President, Driessen drives higher revenue by increasing efficiency and overseeing new product and upcoming brand roll outs in the THC and CBD markets. Chris directs all operations at Organa Labs, the Organa Brands Fulfillment Center and the Organa Brands Corporate Office.

Chris Driessen is committed to industry advocacy, corporate responsibility, scientific research, product innovation and safe access to cannabis.

Charles P. Rutherford II

Charlie is the Business Development Director at Boveda and his personal story is what informs Boveda’s mission in maximizing the quality of cannabis. In 2013 Charlie was hit on his motorcycle by a careless driver, resulting in amputation of his left foot. Desperate for a more effective and safer relief for phantom limb pain than increasing amounts of opiates, Charlie reluctantly turned to cannabis. In one night, he went from skeptic to believer. The quality of life that cannabis provides allows Charlie to compete in golf, mountain biking, downhill skiing and marksmanship. The only difference before and after the accident, he says, is that now he gets much better parking.

Kevin Jodrey

Kevin Jodrey is one of the most well known growers in Humboldt County and is an internationally respected cannabis expert, known for improving and forwarding the modern cannabis movement. As a world renowned hunter of ganja genetics, Kev is fascinated by the search for rare, desirable, and marketable traits.

Kevin is the creator of Port Royal, owner of Wonderland Nursery, and co-founder of The Ganjier. He’s been a cannabis cultivator for decades, running his own operations and offering consulting services to the broader community. He’s spoken at universities, judged at the Emerald Cup, and consulted on cannabis related educational shows for National Geographic and A&E.

Featured in the New York Times, a pulitzer prize winning Washington Post article, countless other articles, books, and radio, and tv shows, he is at the epicenter of the Green Rush (and graces the walls of the Oakland Museum to prove it) and is guiding the industry as it transitions to legalization.

Clint Younge

Clint Younge had ten years of Sales/PR, and Management experience before entering the Cannabis industry, where he worked his way up from budtender to assistant manager, to manager and brand ambassador before becoming CEO of MMJ Canada. He is a Director of the Canadian Association of Medical Cannabis Dispensaries, and is an advocate who loves connecting people. MMJ Canada has eight stores (and growing) across Canada, and works closely with the LOST Organization, a mental health division that reflects Clint’s main focus with Cannabis.

Michael Robbie

Michael Robbie, P.Eng., MBA.  Michael is the Director of Marketing with Conviron – the world leading designer/supplier of controlled environments for plant growth rooms in the plant research and ag-biotech sectors having installed thousands of units around the world over the last 50 years.  Michael is leading Conviron’s expansion into the cannabis sector, leveraging their designs and technologies proven in the precision-based world of plant science and applying them to commercial cannabis production facilities.

Terry Roycroft

In 2010, Mr. Roycroft founded MCRCI, a private organization with licensed physicians that educate and sign in support of qualified patients looking for legal access and guidance for medicinal cannabis. MCRCI soon became the leading cannabis clinic in Canada with a team of doctors who specialize in prescribing cannabis. With his knowledge and experience in the medicinal cannabis industry, Mr. Roycroft soon became one of the top consultants in the country for the Marihuana for Medical Purposes Regulations (MMPR) and the former Marihuana Medical Access Regulations (MMAR). Mr. Roycroft continues to expand his network and database within the industry, locally and internationally, by working with production sites, pharmacists, medical laboratories, doctors, and patients. Mr. Roycroft has recently done talks in Australia to the College of Physicians and a number of talks across Canada to HR groups regarding medicinal cannabis in the workplace.

Maxim Zavet

A successful lawyer and businessman who knows firsthand how the naturally healing power of cannabis can replace traditional medicines, Max has taken his incredible passion for cannabis and transformed it into a company dedicated to helping others. From the extremely approachable and knowledgeable customer service team to the carefully selected strains available, Max wants every aspect of the #EmblemExperience to be a positive one.

 


Leave a comment

Hemp Cannabinoid Innovator Isodiol® and CBD Naturals® Set to Launch New Lifestyle Brand CBDXtreme™ at ASD Market Week in Las Vegas

CARLSBAD, CA / ACCESSWIRE / March 18, 2017 / Isodiol®, the industry’s most innovative hemp cannabinoid product developer and manufacturer, is proud to announce that it has developed the new lifestyle brand, CBDXtreme™ with CBD Naturals®. CBDXtreme™ offers a unique line of vape, dab and edible products to meet the demands of this growing market. Isodiol® is continuing to work with CBD Naturals® to expanded their product line.

CBDXtreme™ will be featured in the Isodiol® booth (# SL3717) at ASD Market Week in Las Vegas March 19-22, 2017. ASD is known as the most comprehensive B2B trade show globally with 45,000 buyers from 88 countries visiting the trade show each year.

As a special promotion for ASD Market Week, Isodiol® and CBD Naturals® are offering an exclusive, limited-time promotion for new wholesale accounts. To learn more about these promotions stop by booth #SL3717 or email info@isodiol.com. CLICK HERE to register to become an authorized CBDXtreme™ reseller.

CBDXtreme™ Product Line:

CBDXtreme H20™ – Powered by the cutting edge science of nanotechnology in NanoUltra™, this water-soluble formula provides optimum delivery of hemp’s powerful phytocannabinoids along with Electrolytes, Potassium, Calcium, Magnesium, Methyl B12, and CoQ10 to help support physical stamina and mental acuity.


AMP’D UP™ Energy Shot – This proprietary formulated energy shot combines nano-emulsified phytocannabinoids, over 75 botanical terpenes, B-vitamins and premium caffeine for a boost of energy without the crash.

View photos

CHEWit™ – The Tayberry gummies help promote healthy bones and stronger immunity with Heneplex™, Vitamin D3 and B12. Acaí Blueberry gummies add prebiotic fiber, probiotic cultures and Heneplex™ for digestive health and balance.

View photos

ADDit™ – This unique beverage and e-juice additive delivers full-spectrum phytocannabinoids and terpenes to support overall wellness and balance.

VAPEit™ – These phytocannabinoid and herbal adaptogenic e-liquids support overall function and increased vitality. Available in Strawberry Kush, Raspberry Cough and Grape Ape flavors.

View photos

DABit™ – These TruSpectrum™ hemp extracts are available in crumble, distillate and isolate form for use in dab rigs or vaporizers.

CLICK HERE to register to become an authorized CBDXtreme™ reseller.

About Isodiol®

Isodiol® and its team of collaborators grow and harvest hemp on an industrial scale, and then process it to extract the non-psychoactive cannabidiol (CBD) to the highest available purity for worldwide distribution.

View photos

By utilizing one of the world’s largest hemp farms, Isodiol and its partners are the choice for industrial volumes of high-grade, THC-Free CBD. Pharmaceutical, nutraceutical and cosmetic companies worldwide have gained market share due using Isodiol products.

To follow Isodiol online, visit the Company’s website at http://www.isodiol.com or Facebook, Instagram, and Twitter.

About CBD Naturals®

Carlsbad Naturals, LLC, is a subsidiary of Laguna Blends, Inc. (CSE: LAG) (OTC: LAGBF) (Frankfurt: LB6A.F) and operates the brand names CBD Naturals® and CBDXtreme™. The CBD Naturals® brand offers a proprietary hemp infused water beverage and other innovative nano-infused hemp products manufactured by Isodiol.

To learn more, visit https://cbdnaturals.com/, Facebook, or Instagram.

DISCLAIMER

Any and all statements made in this article in regard to Isodiol and its CBD/Cannabidiol products are not expressed as medical claims. Our intention is to initiate conversation, not to suggest results nor to encourage action on the part of the reader. Isodiol is not responsible for and expressly disclaims all liability for damages of any kind arise out of use, reference to, or reliance on any information contained herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat, or cure any disease. Always check with your physician before starting a new dietary supplement program.

LEGAL DISCLOSURE

Isodiol® does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). Cannabidiol is a natural element of industrial hemp. Isodiol’s products are not intended to cure, treat or mitigate any disease states.

*The hemp oil used in Isodiol’s products is produced with ECO certified industrial hemp and only the exempted parts are utilized. The phytocannabinoids in this oil, including CBD, are naturally occurring constituents and free of THC.

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

Contact:
Isodiol S.A.
Rue du Mole 1 c/o
Athemis Gestion SA
2000 Neuchatel/Switzerland

CONTACT:

Phil Cenedella

888.206.3264

phil@isodiol.com 

Source: Isodiol S.A.


Leave a comment

Cannabis Researchers Are Fed Up with Ditch Weed Supplied by the Federal Government — “Inhaling that would be like eating an apple, including the seeds inside it and the branch it grew on.”

https://www.merryjane.com/health/government-grown-dirt-weed-harming-research

In the classic stoner flick Half Baked, Dave Chappelle’s custodian character gets his hand on an endless stash of free weed from a government sanctioned federal research facility. But while Chapelle grabbed bricks of Maui Wowie and other high-grade strains to sell on the streets of Manhattan, it turns out that the government’s real-life stash is actually full of low-grade shwag barely fit for toking, and the researchers tasked with studying it very unhappy about it.

“It didn’t resemble cannabis. It didn’t smell like cannabis,” physician Sue Sisley told PBS News Hour about the weed she received from the government program. Sisley is working with the Multidisciplinary Association for Psychedelic Studies (MAPS) in a groundbreaking study looking at the effects of cannabis on military veterans suffering from PTSD.  But with the quality of cannabis supplied by the government program, their research is suffering greatly.

Since 1968, the federal government has only sanctioned one farm, at the University of Mississippi, to grow cannabis for clinical research. The farm, which you can see an aerial view of below, is run by the National Institute for Drug Abuse (NIDA) and is responsible for the stemmy, pale shake that Sisley and her team were sent. And while the Mississippi weed was touted at 13% THC, Sisley’s team tested the schwag and found that it barely hit 8%.

To get a cannabis expert’s opinion, The Washington Post asked professional marijuana critic Jake Browne’s opinion of the government goods. Needless to say, he was not impressed.

“That is, flat out, not a usable form of cannabis. In two decades of smoking weed, I’ve never seen anything that looks like that,” Browne said. “People typically smoke the flower of the plant, but here you can clearly see stems and leaves in there as well, parts that should be discarded. Inhaling that would be like eating an apple, including the seeds inside it and the branch it grew on.”

But not only is the NIDA weed barely recognizable, it also happens to be contaminated. During their testing, Sisley and her team found mold and other pathogens at levels much higher than most weed found in legal state dispensaries. For the MAPS team, that might be the most challenging aspect of the whole ordeal.

“Our biggest concern is patient safety,” Mike Van Dyke, chief of toxicology with the Colorado Department of Public Health and Environment, which is funding the MAPS-sponsored study on PTSD, told PBS. “The lack of a federal regulatory structure makes it a huge challenge. We don’t have all the information we’d like to have.”

It is still illegal for the group to get their buds from dispensaries in legal states, but Sisley isn’t ready to accept the NIDA samples and keep it moving. While the PTSD study will continue with the low quality and potentially unsafe “weed” provided by the government, Sisley has already teamed up with Arizona’s Scottsdale Research Institute on a government proposal that would allow them to grow their own, more potent weed.

“We waited 20 months to get going, and then we got this sub-optimal study drug,” she says. “The longer we allow this monopoly to continue, the more efficacy [of the] research will continue to be thwarted.”

When NIDA was reached for comment about their poor cultivation skills, a spokesman for the institute claimed that they would have better buds in the future.

“There has been some emerging interest from the research community for a wider variety of marijuana and marijuana products. … NIDA does plan on growing some additional marijuana this year and harvest some high THC material that will likely be above 13 percent THC.”

However, if this year’s harvest is any indication, the farmers in Mississippi will have to put in a whole lot of work before they can even come close to growing the high-grade cannabis available on the current market. Until then, don’t expect NIDA-sponsored studies to yield any optimal results.

Written on March 14, 2017 by

Zach Harris

Zach Harris is a writer based in Philadelphia whose work has appeared on Noisey, First We Feast, and Jenkem Magazine. You can find him on Twitter @10000youtubes complaining about NBA referees.


Leave a comment

GERMANY Cannabis on Prescription – everything pharmacists need to know…..from DAZ Online

 

https://www.deutsche-apotheker-zeitung.de/news/artikel/2017/03/09/cannabis-auf-rezept-das-sollte-man-fuers-erste-wissen/chapter:all
STUTTGART – 09.03.2017, 6:00 PM

4

On March 9, 2017, the Cannabis Act was published in the Federal Gazette. This means that cannabis blossoms and preparations in Germany are available from 10 March onwards and can be prescribed by any physician regardless of their specialist field. (Photo: Michael / Fotolia)

The “Cannabis Act” entered into force on 10 March. Now it can be that a patient with a prescription over cannabis blossoms comes to you in the pharmacy. You still have not found time to get closer to the subject? No panic! Here is the first aid in the fast run.

What’s New?

Previously the patient for a cannabis-based therapy had a permit from the Federal Institute for Drugs and Medical Devices (BfArM) seek, as the supplying pharmacy. With the entry into force of the new Act on 10 March 2017, the medical use of cannabis in Germany is no longer a derogation. Cannabis blossoms and preparations are now available in Germany and can be prescribed by any physician independently of their specialist field, but not by dentists and veterinarians. The substances dronabinol and nabilone as well as the finished medicinal products approved in Germany were already listed in Annex III of the Narcotic Drugs Act (BtMG).

more on the subject

MODEL PROJECT

Basel examines cannabis use from pharmacies

MONOGRAPHS PUBLISHED IN THE DAC / NRF

Pharmacists are prepared for cannabis

Another important innovation concerns the reimbursement: the statutory health insurance funds must pay the costs for the therapy with medicinal hemp as a rule. The prerequisite is that in the case of a serious illness, no other generally accepted medical performance standard is available or is associated with intolerable disadvantages. In the case of the first regulation, the health insurance fund must be approved before the start of the service. This is why the patient has to take care of himself (with the help of the doctor).

There is no compulsory medical check-up for the supplying pharmacy, but it is recommended to insure with the health insurance company that the costs are taken over. A decision on the costs must be taken within three weeks after the application, within the framework of an outpatient palliative care even within three days. If the medical service is consulted, a period of five weeks applies. An immediate start of therapy is only possible with the issuance of a private recipe.

Where can I get binding information?

Admittedly, not all questions regarding the medical use of cannabis have been clarified at the present time. On some sources, however, is definitely left.

When BfArM one is in the course of the new law “cannabis agency” established which ensures that sufficient medicinal purposes from state-controlled cultivation is in the required quality. Until all plants are produced in Germany, the supply of cannabis flowers is covered by imports, mainly from the Netherlands and Canada. The BfArM provides information on which cannabis varieties are currently available for an appropriate therapy, but does not answer any questions regarding their application.

The German drug-Codex (DAC) includes the monographs “Cannabis flowers, cannabis flos (C-053)”, “Adjusted, refined cannabis oil resin (C-054)”, “cannabidiol (C-052)” and “Dronabinol (D-100 ) “In which data on testing, storage, labeling, application areas, counter-indications, side effects and interactions are made.

The New Rezepturformularium (NRF) already contains the formulation instructions “dronabinol capsules 2.5 mg / 5 mg / 10 mg (NRF 22.7.)” And “Oily dronabinol drops 25 mg / ml (NRF 22.8.)” In addition, the ” Oily cannabidiol solution 50 mg / ml (NRF 22.10.) “, Which however does not fall under the BtMG. “Cannabis Blossoms for inhalation after evaporation (NRF 22.12.)”, “Cannabis Blossoms in single doses for inhalation after evaporation (NRF 22.13.)”, “Cannabis Blossoms.” The new recipe regulations “Oily cannabis oil resin solution 25 mg / ml Dronabinol (NRF 22.11 (NRF 22.15.) “And” Ethanolic dronabinol solution 10 mg / ml for inhalation (NRF 22.16.) “,” Cannabis flowers in single doses for tea preparation (NRF 22.15.

Reliable information can also be found in the technical information of the registered in Germany finished drug Sativex ® and Canemes ® .

What can be prescribed?

All THC-containing starting materials, preparations and finished medicinal products are subject to the Narcotics Act (BtMG); The applicable rules for the delivery of a BtM recipe as well as the resulting documentation obligations must be observed.

Cannabis Blossoms

The maximum quantity for cannabis blossoms, which may be prescribed for a patient within 30 days, is limited to 100 g. At the moment, the demand for starting material is covered by the Netherlands (from the company Bedrocan BV) and Canada (MedCann GmbH and Peace Naturals) (see table).

The Dutch varieties can be obtained from Fagron GmbH & Co. KG and Pedanios GmbH, the Canadian flowers from Peace Naturals by Pedanios.

Due to the content of tetrahydrocannabinol (THC) and cannabidiol (CBD) in the cannabis blossoms, the therapy can be controlled. Thus, it is possible for the patient to prescribe different cannabis varieties in parallel. On the BtM-recipe must therefore also be explicitly noted by the doctor in addition to the indication “Cannabis-Blüten” the concerned varieties. For example, 100 g of the sorgcan variety as well as 50 g of each of the varieties sorgcan and bedica could be prescribed. If the regulation exceeds the maximum permitted level, the recipe must be marked with the exception “A”.

THC / CBD content of the varieties of cannabis blossoms offered

variety THC content Salary CBD
Varieties offered by Bedrocan BV
Threads Approx. 22% <1%
Threatbinol Approximately 13.5% <1%
Bedica granulated * Approximately 14% <1%
Bediol granulated * Approximately 6.3% Approx. 8%
Bedrolite granulated * <1%    Approx. 9%
Offered by MedCann GmbH
Princeton (MCTK007) About 16.5%   Up to 0.05%
Houndstooth (MCTK001) Approximately 13.5% Up to 0.05%
Penelope (MCTK002) Approximately 6.7% Up to 10.2%
Argyle (MCTK005) Approx. 5.4% Approx. 7%
Offered by Peace Naturals
Pedanios 22/1 Approx. 22% Up to 1%
Pedanios 18/1 Approx. 18% Up to 1%
Pedanios 16/1 Approximately 16% Up to 1%
Pedanios 14/1 Approximately 14% Up to 1%
Pedanios 8/8 Approx. 8% Approx. 8%

* Granulated means that the dried flowers in max. 5 mm in size were crushed

For the purpose of the identity check, please refer to the DAC monograph “Cannabis Blossoms, Cannabis Flos” (C-053) and the alternative methods of the DAC.

The recipe regulations NRF 22.12. To 22.15. Contain instructions for delivering cannabis blossoms to the patient. To prepare, cannabis flowers are coarsely ground in a closed herbs mill and then sieved (2000 μm). Usually 5-g doses are prescribed. Dosing by the patient is then carried out by means of a dosing spoon. However, it may also happen that individual doses are desired by the doctor, for example, 10 times 1 g. In this case, the pharmacy must weigh the portions, portion them and fill them in suitable containers (see NRF 22.13.).

Well, a doctor is not obligated to prescribe NRF recipes so that recipes can also be made via unbrewned cannabis blossoms.

The first order of cannabis blossoms is presumably “application according to written instructions”. However, the operating instructions with individual and daily doses must be available in writing to the supplying pharmacy, as this must be recorded on the primary packaging. In follow-on doses, the dosage on the prescription is usually indicated.

Cannabis blossoms can be inhaled or orally taken. For inhalation, the use of an electric evaporator is recommended, in which a certain quantity of cannabis blossoms is heated to a temperature of 180 to 210 ° C. Currently, two certified medical products are registered in Germany (Volcano Medic, Vaporisator Mighty Medic). For the oral application of cannabis blossoms in the form of a tea, the NRF recipe regulations 22.14. And 22.15. he is working.

The issue of settlement of cannabis flowers answers the Federal Chamber of Pharmacists on its website (the protected area) as follows: “If the cannabis flowers transferred to the natural state, bottled, packaged or labeled delivered to the patient, the price to be § 4 AMPreisV form . If cannabis flowers according to NRF rules, that is under crushing and sieving of the drug and, if necessary, processed packaging in single doses to a recipe medicine products applies, § 5 AMPreisV . Plus pharmacies can calculate 7 AMPreisV amounting to EUR 0.26 including Umsetzsteuer narcotics fee under § “. (Editor’s note: The latter narcotics charge is, with the entry into force of the Drug Supply Support Act 2 91 Euro rise) . The special Pharmazentralennummer 06460665 has been established for the settlement of prescriptions for cannabis-containing and cannabis-containing preparations (prescription medicines).

Prescriptions with dronabinol

If Dronabinol (= THC) is prescribed as a pure substance, the doctors normally refer to the two NRF formulations that can be made in the pharmacy: “Olyige Dronabinol capsules 2.5 mg, 5 mg and 10 mg (NRF 22.7 ) “And” oily dronabinol drops 25 mg / ml (NRF 22.8) “. The formulation substance can be ordered from THC Pharm GmbH, Bionorica Ethics GmbH and Fagron GmbH. The DAC monograph “Dronabinol” (D-100) contains rules for the identity test.

For the taxation of dronabinol drops, a 90% surcharge is added to the cost of the recipe substance amounts used or the recipe set. Five Euros are calculated for making solutions using heat up to 300 grams. The total amount is 19 percent VAT plus the BtM prescription fee of 0,26 Euro. In the case of Dronabinol capsules, the prescription surcharge amounts to five euros for the filling of capsules up to the basic amount of twelve pieces seven euros.

Finished medicinal products

Currently, the finished drug Sativex in Germany ® and Canemes ® approved. On the BtM recipe, the preparation must be mentioned by name and clearly determine the amount per separate form.

The oral spray Sativex ® contains the standardized extract nabiximols and is approved for symptom improvement in adults with moderate to severe spasticity due to multiple sclerosis (MS). The patient takes 2.7 mg of THC and 2.5 mg of CBD per dose as a single dose.

Canemes ® contains the active substance nabilone as a fully synthetically manufactured derivative of delta-9-tetrahydrocannabinol and is indicated for treatment of nausea and vomiting associated with chemotherapy in adults who do not respond adequately to other anti-emetic treatments.

It is also possible that recipes on foreign-registered preparations are issued, which may be introduced as a single imports into Germany, for example, approved in the US Marinol ® . The special code 06460671 has been established for the settlement of prescriptions for cannabis-containing finished medicinal products without a pharmaceutical central number (imports pursuant to section 73 (3) of the German Medicinal Products Act).

Extract of cannabis flowers

A cannabis-full extract is to become an official component of the Bionorica Ethics range from June 2017 onwards. This is a flower extract for oral use which is adjusted to a content of 5% THC and is delivered among other things in 10 g bottles. The DAC contains the monograph “Adjusted refined cannabis oil (C-054)”. There is a prescription of 1000 mg extract within 30 days. To adjust the physically prescribed concentration, the starting extract is diluted with Miglyol, a mixture of medium-chain triglycerides. Further information is contained in NRF 22.11.

The prorated amount of flower extract and the price of the prescription set plus 90% surcharge as well as a prescription surcharge of 2.50 euros for the preparation of a solution without application of heat are given. The VAT and the BTM fee of 0,26 Euro are charged to the total amount.

What should be addressed in the consultation?

The new law explicitly failed to list individual indications for the medical use of cannabis. Theoretically, cannabis blossoms and extracts as well as prescription drugs with dronabinol could therefore be prescribed for every indication. Irrespective of the area of application, the patient should be given some words when they are handed over.

dosage

For the dosage of cannabis as a medicine, there are no general rules, but recommendations. Regardless of whether they are blossoms, extracts, formulations or finished medicinal products, it is essential to titrate the correct dose slowly for a long-term therapy. This may take several weeks. During this time the patient should not drive a vehicle. The application should always be carried out under the same conditions, ie before, at or after meals and at the same time.

For cannabis blossoms, an initial dose of 25 to 50 mg cannabis blossoms is recommended depending on the THC content and a maximum of 100 mg cannabis blossoms with a low THC content per day. The dose can be increased by approximately 25 to 100 mg cannabis blossoms every one to three days. For inhalation, a vaporiser is recommended (see NRF 22.12 and 22.13.). It is also possible to use as a tea, but with a lower yield (see NRF 22.14 and 22.15.).

Concerning formulations with dronabinol, 2.5 mg dronabinol should be started with once or twice daily and the dosage carefully adjusted within four weeks every one or two days by one unit (2.5 mg dronabinol) until the desired effect or effect is achieved Occurrence of side effects. Oar drops of dronabinol should not be diluted with water for oral administration, but should be taken either directly on a spoon or on a piece of bread, a biscuit or a diced sugar.

The adverse effects of Sativex ® is started with a puff in the evening. The patient can gradually increase the dose by one spray per day to a maximum of twelve spray shocks daily. Spray gaps should be at least 15 minutes apart.

When finished medicinal Canemes ® , a dosage of one to two capsules (1.0 or 2.0 mg nabilone) per day is common.

The extract from cannabis blossoms usually starts with a single dose of 2.5 mg dronabinol daily. It is sensible to drop the drops directly into a spoon. Alternatively, they can be taken on a piece of bread, a butter biscuit or on a piece of sugar. Do not inhale the drops.

Side effects

Especially at the beginning of therapy, dizziness and fatigue often occur. Side effects such as tachycardia, blood pressure drop, mouth dryness, muscle relaxation, increased appetite and psychotropic effects are also possible. When taken regularly, however, usually a habituation occurs.

Contraindications

Personality disorders, psychotic disorders, severe cardiovascular diseases, pregnancy and lactation are important contraindications.

Interactions

Interactions with substrates of the cytochrome P450 system (CYP450) are possible, including CYP inhibitors such as itraconazole, ritonavir or clarithromycin and CYP inducers such as rifampicin, carbamazepine and phenytoin. Pharmacodynamically, the sedative effects of benzodiazepines and hypnotics and the muscle-relaxing effect of spasmolytics can be enhanced.

Overdosage

In case of overdose of the finished product Sativex ® acute intoxikationsartige reactions including dizziness, hallucinations, delusions, paranoia, tachycardia or bradycardia were observed with hypotension.

ISBN 978-3-7692-6819-5. German pharmacist publishing house 2017

The Bay

Cannabis: Work aid for the pharmacy

Klaus Häußermann, Franjo Grotenhermen, Eva Milz

The song “Legalize it!” Was awarded the title of “Cannabis” as a medicine in 1976 – and landed on the index in 2016. Father Beimer in Lindenstraße alleviates his parkinsons symptoms with grass and has the nation on his side. A long way – but now is the time: Cannabis on prescription from the pharmacy! This scenario is brand new and raises unusual questions:

  • What varieties and dosage forms of cannabis are available?
  • Who is prescribed what legal basis?
  • What are the indications for cannabis?
  • What are the effects, effects and side effects for the patient?
  • How is procurement, storage and testing performed at the pharmacy?

The authors, proven experts for BtM and cannabis-based drugs, provide you with a compact work aid for the pharmacy. Take advantage of this knowledge!

Rika noise , pharmacist
redaktion @ German-pharmacist-newspaper

 


1 Comment

Germany now leads the world as Medical Marijuana for patients law goes into force today!

BREAKING NEWS FROM THE DHV IN BERLIN:

The law for Cannabis as Medicine was today in the Federal Law Gazette
published and thus enters into force tomorrow:
https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl117s0403.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl117s0403.pdf%27%5D__1489050024671

Press release of the German Hemp Association from 09.03.2017
https://hanfverband.de/nachrichten/pressemitteilungen/gesetz-fuer-cannabis-als-medizin-tritt-in-kraft

Law for Cannabis as Medicine comes into force

Doctors in Germany can from tomorrow for many diseases
prescribe cannabis flowers and extracts by prescription, in severe
Cases at the expense of health insurance. The German Hemp Association
welcomes this development, which for a real relief Affected
will be.

Not only pain patients, but also many other affected
Patients who, for example, from sleep disorders, ADHD or depression
suffer, can thus in the future prescription cannabis from the pharmacy
receive.

This step is a milestone for all parties concerned and the
whole movement is to legalize cannabis in Germany. After
decades of ignoring the suffering of patients in
Germany, the government finally relented. this happens
but not out of pure humanity. The government also wanted to
prevent the right to self-cultivation of patient of them always
more German courts were given because of their emergency.

Given Georg Wurth, director of the German Hemp Association:

“The government has clearly stated that the law of the home-grown by
to prevent patients. For us, this is unacceptable. Of the
German Hemp Association continues to call for the possibility for affected
Patients to grow their cannabis themselves. ”

The reasons for the self-cultivation are manifold:

“In addition to cost savings for the health insurance is the huge
Varieties in cannabis an issue. Some patients may have positive
Experience with a particular variety and want to continue
use “, Georg Wurth continued.

Nevertheless, today dawns a new era in Germany. In the
next few years is very likely the general picture,
which prevails in Germany on cannabis, massively change. From
the drug to drug, from harmful devil for healing
Natural product of the risk for young people a blessing for the sick.

The director of the German Hemp Association also believes that
Need for education in society:

“Especially in southern Germany, the people have to get used to it,
to experience cannabis users in everyday life. The police will
have advised that patients consume public Cannabis
allowed.”